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Abstract 
Background: Atrial fibrillation (AF) is the most common significant arrhythmia, affecting almost 3% 
of the adult population in Sweden. Although AF is associated with increased risk of lower quality of 
life, heart failure, stroke and mortality, the therapeutically options are still limited. Hypertension is a 
common cardiovascular disease affecting approximately one third of the adult population, and is the 
underlying cause for more AF cases than any other disease. Almost 10% of the hypertension cases 
may be due to primary aldosteronism, a condition that can be treated by a specific therapy. Little is 
known regarding the prevalence of primary aldosteronism in the general population and in the AF 
population. Moreover, current data suggest that AF is overrepresented among hypertensive patients 
with primary aldosteronism. 
 
Major research question: The present thesis aims to evaluate the possibility of screening for primary 
aldosteronism in the AF population, and to estimate the prevalence of primary aldosteronism in the 
AF population. Furthermore, this thesis aims to assess the role of blood pressure levels and lipid 
profile in preventing new-onset AF in the hypertensive population. 
 
Methods: In Study I, 149 AF patients < 65 years were screened for primary aldosteronism by using 
the aldosterone to renin ratio. In the case-control Study III, all AF cases in Sweden between 1987 and 
2013 (N=713,569) were identified by using the Swedish Patient Register. An age, sex and place of 
birth matched control-cohort without AF was randomly selected from the Swedish Total Population 
Register with a case to control ratio of 1:2 (N=1,393,953). The prevalence of primary aldosteronism 
for the individuals alive on 31 December, 2013 in both cohorts was calculated through linkage to the 
Swedish Patient Register. Studies II and IV utilized the primary care hypertensive population in the 
Swedish Primary Care Cardiovascular Database (SPCCD). Approximately 50,000 hypertensive 
patients without AF were followed-up between 2002 and 2008, and dichotomized according to AF 
development or not. The in-treatment blood pressure and lipid profile were compared between the 
new-onset AF group and the no-AF group.  
 
Results: Four individuals (2.6%) of the screened AF population were found to have undiagnosed 
primary aldosteronism. The prevalence of primary aldosteronism in December 2013 was 0.056% in 
the AF cohort and 0.024% in controls. Besides, lower in-treatment systolic blood pressure was found 
to be associated with lower risk of new-onset AF. Paradoxically, total cholesterol and low-density 
lipoprotein cholesterol were found to have an inverse association with new-onset AF. 
 
Conclusions: Assessment of aldosterone to renin ratio can be useful for identification of underlying 
primary aldosteronism in patients with diagnosed AF and hypertension. This recommendation is 
strengthened by the finding of a doubled risk for primary aldosteronism in the AF population com-
pared to matched controls without AF. Moreover, successful blood pressure control in hypertensive 
patients may reduce the risk of new-onset AF. Finally, the underlying mechanism regarding the 
dyslipidemia paradox in AF development is unclear. 
